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Abstract 
Study Design. An experimental study investigating osteoclastic activity induced by rhBMP-2 in sheep. 
Objective. To examine the effects of increasing local rhBMP-2 concentration on osteoclastic response and 
peri-implant bone resorption. 
Summary of Background Data. Level I clinical studies have established the safe and effective volume and 
concentration of rhBMP-2 delivered on an absorbable collagen sponge. However, peri-implant bone 
resorption appearing as decreased mineral density has been observed radiographically in rare instances after 
implantation of rhBMP-2 on an absorbable collagen sponge (rhBMP-2/ACS). 
Methods. Bilateral corticocancellous defects were created in the distal femora of 30 adult sheep. 
Combinations of rhBMP-2/ACS implant volume (V) (1V = normal fill or 2V = overfilled) and rhBMP-2 solution 
concentration (x) (1x = normal concentration or 3.5x = hyperconcentrated) resulted in local rhBMP-2 
concentrations of 0x, 1x, 2x, 3.5x, and 7x the estimated effective concentration for this model. Faxitron 
radiography, quantitative CT, histology, and quantitative histomorphometry were conducted in a blinded 
fashion to analyze the effect of the treatments. 
Results. At 1 week, the normal fill-normal concentration implants (1x) produced the least transient 
osteoclastic activity resulting in limited peri-implant resorption. Overfilled-hyperconcentrated implants (2x, 
3.5x) demonstrated moderate resorption zones. Overfilled-hyperconcentrated implants (7x) demonstrated 
extensive osteoclastic activity and marked resorption. Results at 4 and 8 weeks revealed dense osteoid and 
bone in the voids with progressive bony healing. Control defects showed no osteoclastic activity with little to 
no bony healing. 
Conclusion. Increasing the local rhBMP-2 concentration by overfilling the defect with rhBMP-2/ACS or 
hyperconcen-trating the rhBMP-2 solution on the absorbable collagen sponge led to a concentration-
dependent osteoclastic resorption of peri-implant bone. The osteoclastic effect was transient, and progressive 
healing took place over the 8-week survival period. 
 
Bone morphogenetic protein (BMP) is a potent osteoinductive morphogen capable of inducing de novo bone 
formation in ectopic sites and stimulating bony healing and repair in orthotopic bony sites.1-3 In the late 
1980s, the protein BMP-2 was isolated from human demineralized bone matrix (DBM) and cloned to produce 
recombinant human bone morphogenetic protein-2 (rhBMP-2).4 rhBMP-2 was the subject of extensive 
preclinical research that sought to identify the appropriate rhBMP-2 concentration and carrier to produce 
consistent and reproducible bone formation.5-15Based on preclinical data from rat, rabbit, dog, ovine, and 
nonhuman primate models, it became apparent that higher concentrations of rhBMP-2 were required to 
induce consistent bone formation in higher phylogenetic order animals.5-15 In addition, it was demonstrated 
that a carrier was required to deliver the soluble rhBMP-2 protein to the graft site.5,7,10-16 The absorbable 
collagen sponge (ACS) carrier was found to incorporate sufficient amounts of rhBMP-2 while releasing it at a 
rate capable of initiating the bone formation cascade.12-14 
In 2002, Poynton and Lane 17 published a safety profile related to the safety and use of BMPs in spinal fusion. 
They state, " [horizontal ellipsis] BMPs have a role in the regulation of bone turnover via coupled osteoblastic 
and osteoclastic activity. As with fracture healing, the osteoclastic resorption occurs before bone formation by 
osteoblasts. The exact effect of this in spinal fusion is not completely understood. However, large doses of 
BMP may lead to localized areas of resorption. This is not desirable in spinal fusion, and strategies to prevent 
this include careful control of dose and controlled release from the carrier." 
Also in 2002 and following FDA-approved clinical studies, the combination of 1.5 mg/mL of rhBMP-2 on an 
ACS carrier (INFUSE Bone Graft, Medtronic Sofamor Danek, Memphis, TN) was approved as an autograft 
replacement in specific anterior lumbar interbody fusions (ALIF). INFUSE Bone Graft was subsequently 
approved for the treatment of open tibial fractures in 2004 and for certain oral maxillofacial applications in 
2007. Since its introduction in 2002, INFUSE Bone Graft has been used successfully to induce spinal fusion.18-
36 However, with expanded clinical use, rare instances of vertebral endplate or vertebral body resorption have 
been observed after lumbar interbody fusion with various interbody constructs.25,26,29,32,37,38This resorptive 
phenomenon appears as decreased mineral density on computed tomography (CT) scans approximately 3 to 6 
months after surgery.25,26,29,32,37,38Most often, the resorptive zones were transient and fusion subsequently 
occurred.25,26,29,32 
In 2005, Meisel et al reported "reduced mineral density" and "transient regional osteopenia" at 3 months in 
17 patients treated with 12 mg of rhBMP-2 in polyetheretherketone cages following LIF.32 They indicated that 
these areas were resolved by 6 months. Also in 2005, Burkus et al25,26 reported that 14 of 79 (18%) of patients 
developed "transient bone remodeling zones" between 3 and 12 months on CT after ALIF with INFUSE (8.4-12 
mg [1.5 mg/mL]) combined with threaded allograft bone dowels. Similarly, in 2006, Pradhan et al38 reported 
"aggressive resorption" of the graft and endplates after INFUSE use with ring allograft for ALIF, although the 
dose of rhBMP-2 was not reported. In a case report in 2006, Hansen and Sasso 29reported a resorptive 
response with rhBMP-2 (4.2 mg in 2.8 mL [1.5 mg/mL]) after ALIF with ring allograft. 
Although radiographic transient bone resorptive zones have been reported, cellular activity within these 
zones associated with the rhBMP-2 morphogen has not been characterized by histology. The goal of the 
current study was to use histology to characterize and describe chronological cellular activity within transient 
bone resorption zones associated with varying rhBMP-2/ACS concentrations and volumes in the ovine 
corticocancellous distal femur defect model. Quantitative computerized tomography (QCT), histology, and 
quantitative histomorphometry were used to quantify and characterize short-term osteoclastic response and 
bone resorption associated with hyperconcentrating and overfilling rhBMP-2/ACS in uniformly sized ovine 
corticocancellous bony defects at 3 separate postoperative time periods. 
Materials and Methods 
Animal Model 
The ovine corticocancellous distal femur defect model is an established and validated model that has been 
used for the evaluation of bone grafts and bone void fillers.39-42Unlike other models, this model provides for 
relatively uncomplicated surgical access, limited postoperative pain, and sufficient cancellous bone. In the 
current study, the ovine corticocancellous distal femur defect model was used to examine the short-term 
biologic activity of rhBMP-2/ACS under an IACUC-approved protocol. The animal study was conducted in 
compliance with the Guide for the Care and Use of Laboratory Animals published by the National Research 
Council. 
Animal Surgery 
Before surgery, animals were screened by radiography and hematology to rule out preexisting bony 
abnormalities and to exclude sheep with acute and chronic medical conditions. Thirty skeletally mature 
nongravid female sheep (55-75 kg) received bilateral cylindrical corticocancellous defects approximately 8.0 
mm in diameter by 20.0 mm deep on the cranioventral surface of each lateral condyle. Defects were filled 
with 1 of 2 rhBMP-2/ACS implant volumes with 1 of 3 different rhBMP-2 solution concentrations as 
described in Table 1. Approximately 2.0 mm of the defect was filled with bone wax resulting in a bone 
defect volume of 1.0 cm3. The 60 defects were randomly assigned to 1 of the 5 treatment groups with a 
survival period of 1, 4, or 8 postoperative weeks. This resulted in 4 samples per treatment group per time 
point for analysis by computed tomography scan, high-resolution radiography, and histology, and 
quantitative histomorphometry. All analyses were conducted in a blinded fashion. In the ovine model, a 
dose concentration of 0.43 mg/mL of rhBMP-2 on ACS has been used in several studies.9,10,43,44These studies 
provided the basis for selecting 0.43 mg/mL of rhBMP-2 on ACS as the normal dose concentration in sheep 
(1x in Table 1). 
 
With the animal under general anesthesia, blunt dissection was performed, the periosteum elevated, and 
the lateral surface of the distal femur was exposed. A 2.5-mm Kirschner wire was inserted under 
fluoroscopic guidance to establish ideal positioning of the corticocancellous defects. An 8.0-mm diameter 
cannulated drill bit was placed over the Kirschner wire and advanced until an 8.0-mm diameter by 20.0-mm 
deep defect was created. The defect was then irrigated and dried. Following a randomization schedule, the 
appropriate treatment was prepared and inserted into the defect using forceps as shown in Figure 1. As 
directed in the instructions for preparation, the rhBMP-2 solution was allowed to soak on the ACS carrier 
for 15 minutes before implantation. Previous studies have demonstrated that 95% of the rhBMP-2 is 
incorporated into the ACS following a 15-minute soak time and normal handling.20 Thus, if fluid is displaced 
on implantation, most of the rhBMP-2 originally applied to the ACS should be present within the ACS carrier 
and thus contained within the defect. To contain the implant, the defect opening was covered with bone 
wax. Before closure, each animal received an injection of Marcaine into the surgical site and 1 g of 
cefazolin, intravenously. Postoperative monitoring was conducted and each animal was treated with 
analgesics for at least 5 days. 
 
At the appropriate time points, the animals were killed by intravenous barbiturate overdose. Overlying soft 
tissues were sharply dissected from the defect site, and the operative femora were trimmed, labeled, and 
immersed in 10% neutral buffered formalin. 
CT Scan Analyses 
Images of all distal femora were acquired using computerized tomography (GE Discovery PET/CT scanner or 
GE LightSpeed Ultra Scanner; General Electric Co., Fairfield, CT). Distal femur specimens were positioned so 
the condyles faced toward the gantry to duplicate the positioning used to acquire true axial images in human 
patients. Specimens were centered and positioned to ensure the condyles were level. In addition to sagittal 
and anterior posterior scout images, axial volume images were acquired through the entire sample. Slices 
were acquired helically at 1.25-mm thickness. Quantitative 3-dimensional volume measurements were made 
for the 1-week samples using embedded computed tomographic image analysis software (GE Advantage 
Windows Workstation; General Electric Co., Fairfield, CT). 
Radiography 
A high-resolution radiography unit (Faxitron model 43805, Hewlett Packard, McMinnville, OR) and high-
resolution film (Ektascan B/RA Film 4153; Kodak, Rochester, NY) were used to produce a high-resolution 
anteroposterior and lateral radiograph of all 60 femora. Using these radiographs as a guide, the defects on 
the distal portion of each femur were identified and grossly dissected to produce samples for histologic 
analyses. Four 4.5-mm thick sagittal slabs were produced for each femur as the femur was passed through the 
band saw. As sagittal slabs were produced from lateral to medial, the anatomic location of the sagittal slabs 
was labeled. An additional high-resolution radiograph of all 4 slabs from each of the defects associated with 
the 5 treatments at 1, 4, and 8 weeks was produced. After the slab radiographs were made, the slabs were 
trimmed to produce samples for histology. The entire defect with transient bone resorption and remodeling 
was preserved for histology; necessitating large brain slides in some cases. 
Decalcified Histology 
After fixation in 10% neutral buffered formalin, decalcification was carried out in 10% disodium 
ethylenediamine tetra acetate at a pH of 7.3 and 37[degrees]C. After decalcification was effected, samples 
were rinsed briefly in tap water, and processed using a paraffin infiltrator (Hypercenter, Shandon-Lipshaw, 
Chicago, IL) to dehydrate the specimens in graded alcohols, clear the specimens with xylene, and infiltrate the 
tissues with paraffin. Infiltrated tissues were then embedded in paraffin blocks and sectioned. Two slides 
stained with hematoxylin-eosin (H&E), 2 slides stained with Mallory-Heidenhain, and 2 slides stained with 
Wright-Giemsa stain were produced for each paraffin block. Over 1400 histology slides were produced and 
analyzed. 
Quantitative Histomorphometry 
Quantitative histomorphometry was conducted to assess the extent of transient cancellous bone resorption 
and subsequent bony healing in all defects associated with the 5 treatments at the 3 time periods. 
Quantitative histomorphometry was conducted using an image analysis system (Image Pro Plus Software 
version 5.0, Silver Spring, MD). Using the image analysis system, a high-resolution digital image of the entire 
defect as a whole was acquired from the medial stained histology slides. A millimeter scale present in the field 
allowed for spatial calibration of the image analysis system. The size of the defect (area in millimeters square) 
was measured on at least 2 medial sections for each of the 60 femora in the study. All data were normalized 
to 50.3 mm2, which corresponds to the area of an 8-mm defect. 
Statistical Analyses 
Analysis of variance (ANOVA) was used to model and compare QCT data and quantitative histomorphometry 
data. If the differences between all treatment groups were significant, further pair-wise comparisons of 
treatment groups were performed. P values were adjusted using Tukey's method with regard to multiple 
testing. A 0.05 significance level was used for all tests. 
Results 
Radiographic and Histologic-Histomorphometric Results at One Week 
Postimplantation 
One-week quantitative computed tomography results, Faxitron radiographs, and quantitative 
histomorphometry showed that the buffer group (0x) demonstrated no peri-implant bone resorption 
(Figures 2-4). As seen in Table 2, QCT volume measurements showed an average defect size of 0.750 cm3 in 
the buffer control group, which was slightly less than the expected 1.0-cm3 volume. As shown in Figure 3, 
quantitative histomorphometry measurements made in the cancellous aspect of the defect in the buffer 
control group (0x) showed a normalized area of slightly less than 1. Histology from the buffer control group 
showed no osteoclastic activity and minimal osteoblastic activity, most likely associated with the creation 
and slight remodeling of the bony defect. 
 
Of the groups containing rhBMP-2, the normal fill-normal concentration group (1x) induced the least 
amount of peri-implant resorption by QCT and quantitative histomorphometry at 1 week (Figure 3; Table 
2). In most cases, the original defect boundaries were well preserved, although the defect size was 
increased in the samples. Decreased mineral density in peri-implant trabeculae was present in 2 of the 4 
samples. As seen in Table 2, QCT measurements in the normal fill-normal concentration group (1x) resulted 
in an average defect size of 0.985 cm3, which was nearly identical to the 1.0-cm3 defect size in the study 
 
design. As seen in Figure 3, quantitative histomorphometry measurements from the normal fill-normal 
concentration group (1x) were on average twice the original defect size in the study design in cancellous 
regions at 1 week. Mixed regions of osteoclastic resorption and osteoblastic activity with new osteoid were 
present at the periphery of the defects as shown in Figures 5A, B. Intramembranous bone formation with 
numerous hypertrophied osteoblasts at the periphery of the defect was present and occurring 
simultaneously with osteoclastic resorption as seen in Figure 5B. When osteoclasts were present, they 
were found at the periphery of the defect. Some osteoclasts were occupying resorption pits in the peri-
implant trabeculae (Figures 5A, B) or suspended within granulation tissues present in the peri-implant void 
spaces (Figure 5C). Histology showed that peri-implant trabeculae had been resorbed or became 
osteopenic due to osteoclastic activity (Figures 4 and 5A). Consistent with early wound healing, both 
collagen sponge and granulation tissue were present within these defects. 
In comparison, 1-week radiographs, QCT, histology, and quantitative histomorphometry from the overfilled-
normal concentration (2x) and normal filled-hyperconcentrated (3.5x) groups demonstrated an increased 
amount of peri-implant bone resorption (Figures 2-4; Table 2). Qualitatively and quantitatively, these 2 groups 
had resorption zones of similar size, adjacent to the original defect and extending further into peri-implant 
cancellous bone compared with the normal fill-normal concentration (1x) defects. By QCT, the overfilled-
normal concentration (2x) and normal filled-hyperconcentrated group (3.5x) were on an average 2 cm3, i.e., 
twice the size of the original defect size in the study design. Compared with the buffer control group, this 
resulted in 148% and 169% increases in average defect volume by QCT, respectively (Table 2). As seen 
in Figure 3, quantitative histomorphometry measurements from the overfilled but normal concentration 
group as well as the hyperconcentrated but normal volume group at 1 week were on an average 21/2 times 
the size of the original defect size in the study design. Mixed regions of osteoclast resorption and osteoblastic 
activity with new osteoid were present at the periphery of the defect. Osteoclasts were found to occupy 
resorption pits in the peri-implant trabeculae or suspended within granulation tissue. Intramembranous bone 
formation at the periphery of the defect with numerous osteoblasts was present (Figure 5B). Consistent with 
early wound healing, both collagen sponge and granulation tissue were present within these defects (Figure 
5D). 
The overfilled and hyperconcentrated group (7x) showed significant peri-implant bone resorption by Faxitron 
radiographs, QCT, histology, and quantitative histomorphometry at 1 week (Figures 2-4; Table 2). The 
overfilled and hyperconcentrated group (7x) resulted in marked peri-implant bone resorption on CT scans 
(Figure 2). In many instances, the original defect boundary could not be identified, indicating that marked 
osteoclastic activity had occurred. By QCT, the average defect volume was 2.758 cm3, an approximate 268% 
increase compared with the buffer control (0x) group (Table 2). Pair-wise comparisons demonstrated that the 
average defect volume for the overfilled and hyperconcentrated group (7x) was statistically greater than the 
average defect volume for both the buffer control (0x) group and normal fill-normal concentration (1x) group 
(ANOVA, P < 0.05). As seen in Figure 3, quantitative histomorphometry measurements from the overfilled and 
hyperconcentrated group were on an average four and a half times the original defect size in the study 
design. Some defects in the overfilled and hyperconcentrated group were 7 times the initial defect size. 
Statistically significant differences in defect size as measured in cancellous bone with quantitative 
histomorphometry were only found at the 1-week time period. Similar to the QCT measurements, the 
average normalized defect area in cancellous bone as measured by quantitative histomorphometry for the 
overfilled and hyperconcentrated (7x) group was greater than both the buffer control (0x) group and the 
normal fill-normal concentration (1x) group at 1 week (ANOVA, P < 0.05). By histology, the original defect 
margin-boundary in the (7x) group could not be identified, indicating that marked osteoclastic activity had 
occurred within 1 week. Preexisting trabecular structures could be identified on macroscopic histology by 
collections of osteoclasts remaining after removal of the bony structure. Numerous osteoclasts, macrophages, 
and fibroblasts were present within the peri-implant voids and intramembranous ossification was observed at 
the periphery of the voids. 
A common histologic finding for all groups at 1 week was a lack of cortical bone resorption. Bone resorption 
was most prominent in medial cancellous bony samples. Thus, quantitative histomorphometry measured on 
medial samples measured the greatest extent of bone resorption in cancellous bone, and not cortical bone 
loss. Another common finding for all groups at 1 week was the presence of ACS carrier in the original defect 
(Figure 5D). Minimal infiltration of the ACS had occurred at 1 week, although numerous macrophages and 
foreign body giant cells were located on the surface of the ACS, demonstrating cell-mediated degradation 
typical for this resorbable material. Lastly, seromas, hematomas, and florid osteoclastic resorption were 
frequently observed at 1 week. 
Radiographic and Histologic Results at Four Weeks Postimplantation 
Four-week CT scans seen in Figure 6 show bone remodeling limited to the periphery of the bony defects at 
4 weeks in the buffer control (0x) group. As seen in Figures 6 and 7, progressive bony healing was noted in 
the 4-week CT scans and 4-week macroscopic histology in the rhBMP-2/ACS treatment groups. 
Histologically, no osteoclastic activity was present at 4 weeks for any treatment group, suggesting its 
transient occurrence with rhBMP-2/ACS. At 4 weeks, extensive osteoblastic activity, intramembranous 
ossification, and osteoid were present within the defects. This rapid osteoinductive event produced a new 
bone matrix that contained numerous thin trabeculae compared with the thicker native trabecular bone 
present in the metaphyseal portion of the distal femur. Differential staining indicated that some osteoid 
within the defect was partially mineralized. As seen in Figure 7, histologic cross-sections demonstrated that 
some of the cancellous regions of the defects were healing at 4 weeks. 
 
As seen in Figure 3, quantitative histomorphometry measurements at 4 weeks showed that only the buffer 
control (0x) and the normal fill-normal concentration (1x) groups were, on average, smaller than the original 
defect size in the study design in cancellous regions. Although quantitative histomorphometry demonstrated 
progressive bony healing from 1 to 4 weeks for the other 3 groups, the hyperconcentrated and overfilled 
groups still had defects that were on average larger than the original 8-mm defect size (Figure 3). Four-week 
computed tomography scans showed dense de novo bone formation within most peri-implant voids. Less 
residual ACS carrier was found within the defect at 4 weeks after surgery than at 1 week after surgery. 
Seromas and hematomas were still frequently observed at 4 weeks. 
Radiographic and Histologic Results at Eight Weeks Postimplantation 
CT scans showed bone remodeling limited to the periphery of the bony defects in the buffer control (0x) 
group at 8 weeks (Figure 8). Progressive bony healing was noted in the 8-week CT scans and 8-week 
macroscopic histology in the rhBMP-2/ACS treatment groups (Figures 8, 9). Histologically, no osteoclastic 
activity was present at 8 weeks for any treatment group, suggesting its transient occurrence with rhBMP-
2/ACS. At 8 weeks, extensive osteoblastic activity, intramembranous ossification, and osteoid were present 
within the defects. This rapid osteoinductive event produced a new bone matrix that contained numerous 
thin trabeculae compared with the native bone present in the metaphyseal region of the distal femur. 
Differential staining indicated that some osteoid within the defect was partially mineralized. Histologic 
cross-sections demonstrated that some cancellous regions of the defects were completely healed at 8 
weeks. The buffer control group (0x) did not demonstrate significant osteoclastic or osteoblastic activity. As 
seen in Figure 3, quantitative histomorphometry measurements showed that, on average, only the buffer 
control (0x) group was smaller in cancellous sampling than the surgically created 8-mm defect size at 8 
weeks. 
 
As seen in Figure 3, quantitative histomorphometry clearly demonstrated progressive bony healing from 1 to 
4 to 8 weeks. However, as seen in Figure 3, all 4 of the rhBMP-2/ACS groups at 8 weeks still had defects that 
were, on average, larger than the original 8-mm corticocancellous bony defect. Computed tomography scans 
at 8 weeks showed an increase in bony healing of the defects and an increased radiopacity due to de 
novo bone that filled the previously created peri-implant voids (Figure 8). Seromas and hematomas were still 
frequently observed in the histology at 8 weeks (Figure 9). No ACS carrier remnants were observed in any of 
the samples at 8 weeks, demonstrating complete resorption of the ACS carrier. 
Discussion 
FDA-approved clinical investigations have examined rhBMP-2/ACS in threaded allograft bone dowels for ALIF 
surgery, in allograft rings for anterior cervical fusion, and in threaded titanium cages for ALIF and PLIF.19-
26,28 These clinical studies have shown that rhBMP-2/ACS can induce interbody spinal fusion when used with 
interbody spine fusion devices and bone grafts. Transient bone resorption was only observed in 1 of these 
FDA-approved clinical investigations.25,26 In that study, computed tomography scans at 3, 6, and 12 months 
showed that 18% (14 of 79) of the patients treated with rhBMP-2/ACS developed transient areas of bone 
remodeling within the vertebral bodies. These radiolucent remodeling zones were transient, resolving 12 to 
24 months after surgery. A 99% fusion rate occurred in this study at 24 months, despite the presence of these 
transient radiolucent remodeling zones. In that study, investigators placed 5.6 to 8 cm3 of rhBMP-2/ACS (8.4-
12 mg of rhBMP-2) at 1.5 mg/cm3 inside and between the 2 threaded allograft bone dowels in a single-level 
ALIF.25,26 The volume of rhBMP-2/ACS used per bone dowel was determined by the outer diameter of the 
construct. However, because the internal diameter of the dowels was dependent on the diameter of the 
donor's medullary canal, there was variability in each dowel's internal volume. This may have led to 
unanticipated overfilling of some bone dowels and a locally high rhBMP-2 concentration. Furthermore, the 
surgical technique for this procedure required more reaming of the endplates compared with tapered 
interbody fusion cages.23 This may have resulted in increased exposure of mesenchymal stem cells, 
hematopoietic stem cells, and existing osteoclasts on trabecular bone to high doses of rhBMP-2. 
Other clinical series and case reports have described transient bone resorption after the use of rhBMP-2 in 
interbody fusion procedures.29,32,37,38 Meisel et al32reported on a clinical series of 17 patients in which 
posterior lumbar interbody fusion was performed with polyetheretherketone vertebral body spacers and 
rhBMP-2/ACS. In their series, investigators placed 4 cm3 of rhBMP-2/ACS (6 mg rhBMP-2) into each of 2 
vertebral body spacers. The internal volume of each interbody construct was 1.3 cm3. Overfilling the 
constructs in this manner produced a local rhBMP-2 concentration of approximately 4.6 mg/cm3 (6 mg 
rhBMP-2/1.3 cm3 volume), which is more than 3 times the 1.5 mg/cm3 used in the previously cited 
Investigational Device Exemption (IDE) clinical trials involving interbody constructs. Their experience indicated 
that these radiographic observations proceeded to heal without incident during the 12-month follow-up and 
did not require revision surgery. In fact, it was reported that fusion was achieved in all patients by 6 months 
after surgery. 
McClellan et al37 reported enhanced bony remodeling by CT scan at 3 months after surgery associated with 
the use of rhBMP-2 in 26 of 198 patients after transforaminal lumbar interbody fusion with an interbody 
construct and rhBMP-2/ACS. The volume of rhBMP-2/ACS used within and adjacent to the interbody 
construct ranged from 2.8 to 5.6 cm3 for single-level procedures and up to 8.0 cm3 for multilevel procedures. 
Resorptive defects in the vertebral bodies were noted in 22 levels. In the absence of histology, these defects 
were referred to as osteolytic defects and were graded as mild, moderate, or severe. Other published work 
has demonstrated the transient nature of these zones with some of the levels showing bony resorption 
progressing toward fusion, resulting in clinical success.29,32,38 We believe that it is not accurate to describe 
these resorptive zones as osteolytic because (1) osteolytic lesions do not resolve within a short period, (2) 
osteolytic lesions do not actively remodel, and (3) osteolytic lesions do not generate significant new bone 
without further intervention. In the current ovine study, resorptive zones observed with rhBMP-2 were 
transient. QCT and quantitative histomorphometry showed that healing progressed with time and without 
additional intervention. In fact, osteoclastic activity was not observed in any of the treated defects at 4 weeks, 
regardless of treatment. 
In addition to the clinical papers cited, a number of in vitro and in vivo animal studies have demonstrated the 
ability of BMP-2 to upregulate osteoclast activity and bone resorption in a dose-dependent manner.45-
49 Miyaji et al48 showed that BMP-2 (at 0, 100, and 400 [mu]g/mL concentrations) caused a dose-dependent 
increase in dentin resorption through osteoclastic activity in vitro. Rodeo et al50 found that the adjunctive use 
of rhBMP-2 on a collagen sponge accelerated tendon graft healing when placed into bone tunnels in the dog 
proximal tibia. However, they also noted osteoclast-mediated resorption of bone (evident as early as 7 days) 
in the high-dose rhBMP-2 group coupled with vigorous new bone formation adjacent to the bone tunnels. 
Similarly, Sumner et al51 investigated the use of rhBMP-2 to (1) enhance bone ingrowth into porous-coated 
implants and (2) to promote gap healing around the implants. They found that high doses of rhBMP-2 initially 
stimulated net bone resorption in adjacent host bone followed by bone formation. Taken together, these 
studies demonstrate that although the main mechanism of action of osteoinductive proteins is to 
differentiate stem cells and osteoprogenitor cells into osteoblasts, they can also upregulate osteoclastic 
activity at high dose concentrations. 
Further work examining the effects of increasing local concentrations of rhBMP-2 on the ACS carrier could 
include additional short-term studies with more clinically relevant models, perhaps models of lumbar 
interbody fusion. The addition of bisphosphonates, effective as osteoclast and bone resorption inhibitors, 
could be used to examine their effects on the short-term osteoclastic response to rhBMP-2 and long-term 
fusion results. 
Our study was performed to examine the effects of increasing local rhBMP-2 concentration on osteoclastic 
activity in a contained cancellous defect. This is the first study performed in a large animal model with 
analyses of both short-term computed tomography scans and histology. There are several possible limitations 
associated with this study. First, we experienced difficulty in creating a consistent 1.0-cm3 defect in the ovine 
corticocancellous defect model. In determining the depth of the defect, the drill collar and guide were set to 
create a 20-mm length defect on a flat bone surface. Because of the curved lateral surface of the distal femur, 
the drill sleeve may not have been flush with the bony surface, ultimately creating variability in the depth of 
the defect. This may have led to defect volumes less than 1.0 cm3 further simulating overfilling of the defect 
even in some of the normal fill samples. There also was variability associated with position of the defects with 
respect to the medullary canal. The increased availability of host bone cells (including hematopoietic stem 
cells) in the marrow of the medullary canal may have led to an increased osteoclastic response associated 
with high doses of rhBMP-2. In addition, the closer the defect was to the medullary canal, the less dense the 
trabecular bone structure appeared to be. This may have increased the amount of bone resorption compared 
with an osteoclastic response in a denser bony network. Second, the anatomic differences with respect to 
local trabecular structure of the sheep distal femur relative to the vertebral body are a limitation of this study. 
Third, as with any animal model, there may have been interanimal variability with respect to bone 
remodeling. Last, while the use of bone wax was effective to seal and contain the treatments within the bony 
defect in this model, it might have compressed the ACS implants and altered the healing environment or 
further hyperconcentrated the morphogen. 
Despite these limitations, quantitative histomorphometry and QCT measurements from our study showed 
that increasing the local rhBMP-2 concentration by overfilling the defect with rhBMP-2/ACS or 
hyperconcentrating the rhBMP-2 solution on the absorbable collagen sponge led to a concentration-
dependent increase in peri-implant cancellous bone resorption at 1 week. The osteoclastic resorption was 
transient, and histology demonstrated that osteoclastic activity was not observed at or after 4 weeks. By 4 
weeks, osteoclastic activity in all groups had ceased and was replaced with osteoblastic activity and vigorous 
new intramembranous ossification. Progressive healing of the transient resorption defects took place over the 
8-week survival period. Clinically, the transient resorptive response has infrequently been reported. Using the 
FDA-approved rhBMP-2 concentration and matching the volume of rhBMP-2/ACS with the volume of the 
bony defect or internal cavity of the device may limit the occurrence of transient bone resorption. 
Key Points 
* Increasing the local rhBMP-2 concentration by overfilling a bony defect with rhBMP-2/ACS or 
hyperconcentrating the rhBMP-2 solution led to concentration-dependent osteoclastic resorption of peri-
implant cancellous bone. 
* Osteoclastic activity was transient, with no osteoclastic activity observed in any treatment at 4 weeks after 
surgery. 
* Extensive osteoblastic activity and intramembranous bone formation was present at 4 weeks and continued 
through the 8-week survival period. 
* Using the FDA-approved rhBMP-2 concentration and matching the volume of rhBMP-2/ACS with the volume 
of desired bone formation may limit the occurrence of transient bone resorption. 
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Table 1. Treatment Groups With Volume and Concentration of the Morphogen 
Effective 
Concentration 
Volume and 
Concentration of 
Morphogen 
Treatment Group 
0x 
 
1 cc of (0.00 mg/mL) 
rhBMP-2/ACS 
Buffer control group 
1x 
 
1 cc of (0.43 mg/mL) 
rhBMP-2/ACS 
Normal volume and normal 
concentration 
2x  
 
2 cc of (0.43 mg/mL) 
rhBMP-2/ACS 
Overfilled and normal 
concentration 
3.5x  
 
1 cc of (1.5 mg/mL) 
rhBMP-2/ACS 
Normal volume and 
hyperconcentrated 
7x  
 
2 cc of (1.5 mg/mL) 
rhBMP-2/ACS 
Overfilled and 
hyperconcentrated 
 
 
Figure 1. A, Implant preparation. B, Insertion of the Kirschner wire. C, Verification of Kirschner wire position using 
fluoroscopy. D, Creation of 8.0- x 20.0-mm defect using cannulated drill bit, drill collar, and drill sleeve. E, Empty defect 
following irrigation. F, Insertion of implant into defect. 
 
Figure 2. Axial computed tomography scans at 1 week show increased peri-implant cancellous bone resorption with 
increased effective concentration (conc.). Cortical bone resorption at the lateral aspect of the corticocancellous defect was 
not observed in any of the treatment groups. 
 Figure 3. Quantitative histomorphometry results for medial cancellous bony samples for all treatments at all time periods. 
Data are normalized to an 8-mm defect that has an area of 50.3 mm2. Quantitative histomorphometry showed that 
increasing the total rhBMP-2 dose (by overfilling the defect or by hyperconcentrating rhBMP-2 on the ACS carrier) led to 
transient cancellous bone resorption followed by bony healing that progressed with time. 
 
Figure 4. Decalcified macroscopic histology images (Mallory Heidenhain stain) at 1 week show increased trabecular bone 
resorption with increasing effective concentration (conc.). Mature native bone seen in dark red; dark blue within the 
original defect represents the ACS; and light blue represents granulation tissue and heightened cellular activity 
(osteoclasts). Note that in the overfilled and hyperconcentrated group, osteoclasts were found in peri-implant tissues 
following resorption of native trabecular bone (arrows). A millimeter ruler was placed in the field for scale reference. 
 
Table 2. One-Week Postoperative Mean Defect Volumes (cm3) and the Percentage Volume Increase Compared With the 
Buffer Control 
 
Effective Concentration (rhBMP-2) Mean Defect Volume (cm3) Percent Increase to Control 
0.0x (buffer control) 0.749 ± 0.150 NA 
1.0x 0.985 ± 0.243 32% 
2.0x 2.015 ± 0.771 169% 
3.5x 1.858 ± 0.808 148% 
7.0x 2.758 ± 0.630 268% 
 
 
Figure 5. A, Osteoclastic activity and Howship's lacunae on native bone at the periphery of the bony defect in the 1x group 
at 1 week after surgery (Wright-Giemsa stain, original magnification = 200x). B,Hypertrophied osteoblasts and 
intramembranous ossification (blue) on existing rarified trabeculae (pink) in the 2x group at 1 week after surgery. 
Osteoclasts are observed on the rarified trabeculae (pink) at 1 week. (Wright-Giemsa stain, original magnification = 
79x). C, Osteoclasts suspended within granulation tissue present in peri-implant void spaces in the 1x group at 1 week 
(Wright-Giemsa stain, original magnification = 200x). D, Residual collagen sponge with minimal cellular infiltration in the 
center of the bony defect in the 2x group at 1 week (H&E stain, original magnification = 79x). 
 
 
Figure 6. Axial computed tomography scans at 4 weeks show progressive healing of the defect. Bone wax that migrated into 
the defect may have limited bony healing at the defect opening. 
 
 
Figure 7. Decalcified macroscopic histology images (Mallory Heidenhain stain) at 4 weeks show dense new bone formation 
within the peri-implant voids and original defect. In these images, healing appears to be more complete in the normal fill-
normal concentration (1x) group. A millimeter ruler was placed in the field for scale reference. 
 
 
Figure 8. Axial computed tomography scans at 8 weeks show progressive healing of the defect. Bone wax that migrated into 
the defect may have limited bony healing at the defect opening. 
 
 
Figure 9. Decalcified macroscopic histology images (Mallory Heidenhain stain) at 8 weeks show dense new bone formation 
within the peri-implant voids and original defect. In these images, healing appears to be more complete in the normal fill-
normal concentration (1x) group. A millimeter ruler was placed in the field for scale reference. 
